Who would have thought a mid-week break would halt the stock market’s winning streak? Maybe the hot PMI reading leaked, or traders and investors felt the stock market was getting…
In this edition of StockCharts TV‘s The Final Bar, Dave recaps a day where technology shares struggles, with leading names like NVDA and MU dropping bearish engulfing patterns to indicate short-term distributions.…
In this edition of StockCharts TV‘s The Final Bar, Dave answers viewer questions on using technical indicators on leveraged and inverse ETFs like SOXL and SOXS, buying breakouts below the 200-day moving…
Former President Trump’s first day in court for a hearing to determine the lawfulness of Special Counsel Jack Smith’s appointment in the classified document investigation concluded Friday without a decision…
Thanks to a tidal wave of fundraising following his conviction in the first criminal trial of a former or current president, Donald Trump has all but erased President Biden’s once…
Biden’s secret weapon in previous national debates may again be a factor during showdown with Trump
Amid the circulation of videos on social media in recent weeks which appear to show President Biden’s mental acuity dwindling and a recent Wall Street Journal report adding fuel to…
Former President Trump released a video Thursday mocking independent candidate Robert F. Kennedy Jr. for not meeting the requirements to appear at the first presidential debate. The short video, recorded…
Kim Jong Un prompts health speculation as experts declare: ‘doesn’t look like a healthy man’
North Korean leader Kim Jong Un has raised another round of speculation about his health following publication of photos from his meeting with Russian President Vladimir Putin. ‘I don’t know…
Editor’s Note: This article was originally published on November 21, 2022. This article has absolutely nothing to do with trend following or the markets. I have two friends; one whose…
Gilead Sciences’ (GILD) new HIV prevention shot, lenacapavir, hit it out of the park in a late-stage trial, showing 100% effectiveness. 2,000 women participated in the trial, and none of…